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Abstract 
Background: The majority of allergic patients are poly-sensitized. For causal treatment by allergy immunotherapy 
(AIT) a single or few allergen products containing the clinically most relevant allergens are applied, but few data on 
tolerability of multiple application of AIT is available. The aim of our study was to investigate safety and tolerability in 
patients who started treatment by sublingual immunotherapy (SLIT) with the standardised SQ® grass SLIT-tablet and 
were treated with concomitant AIT products.
Methods: In a non-interventional, open-label, observational study in Germany treatment of patients with the SQ® 
grass SLIT-tablet and concomitant AIT (SCIT or SLIT) was documented between January 2012 and January 2014. 
Patients were followed at visits at first administration of the SQ® grass SLIT-tablet and after 1–3 months of treatment. 
Tolerability of the treatment with the SQ® grass SLIT-tablet and concomitant AIT were assessed by the physician and 
administration of AIT and adverse events (AEs) were recorded by the patients in diaries. AEs and adverse drug reac-
tions (ADRs) were coded by using the Medical Dictionary for Regulatory Activities.
Results: In total, 181 patients were documented by 48 allergists and 160 patients treated with a concomitant AIT 
(SCIT 130, SLIT 30). AEs were reported in 58 (36.3 %) patients with concomitant AIT, and AEs considered related with 
the SQ® grass SLIT-tablet in 49 (30.6 %) and with concomitant AIT in 18 (11.3 %) patients. Treatment was discontinued 
due to ADRs in 12 (7.5 %) patients and severity of ADRs was assessed mild or moderate in 29 (18.1 %), and severe in 
20 (12.5 %) patients. Most common reactions were localised at the application site of the SQ® grass SLIT-tablet as oral 
pruritus, throat irritation, oedema mouth and paraesthesia oral; no serious ADRs were reported. Overall tolerability of 
the SQ® grass SLIT-tablet if given with concomitant AIT was assessed as “good” or “very good” by 91.0 % of patients 
and 91.6 % of physicians.
Conclusions: In comparison to data from previous studies no increase in frequency of AEs or change in the tolerabil-
ity profile was observed when SLIT with the SQ® grass SLIT-tablet was administered with concomitant SCIT or SLIT.
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Background
According to epidemiological data [1, 2], the majority of 
allergic patients are poly-sensitized, with their pattern 
of sensitization varying with the geographical region 
[3]. Today, the treatment of allergic diseases is based 
on allergen avoidance, pharmacotherapy for symptom 
relief, and allergy immunotherapy (AIT) [4]. For specific 
allergy treatment by AIT allergens are applied that have 
been identified as causal for allergic symptoms in order 
to modify the immune response to induce specific immu-
nological tolerance [5]. The common practice of AIT, i.e. 
with subcutaneous application is different in Europe and 
the USA. While in the US patients are treated by prepa-
rations containing all allergens for which a sensitization 
has been detected as a mixture, in Europe AIT products 
containing single allergens are used and one or a few dif-
ferent allergen products are applied to treat the clinically 
most important seasonal and/or perennial allergies [3, 6].
Subcutaneous allergen injections have been primarily 
the main approach for the administration of AIT, how-
ever, this has subsequently been extended to sublingual 
administration, which offers several advantages com-
pared with the subcutaneous route, including a better 
safety profile, increased convenience and at home admin-
istration [7–10].
The majority of patients treated with AIT may probably 
develop symptoms caused by several allergens over an 
extended period of the year, but only a small proportion 
of these patients are probably treated with more than one 
single allergen product. In a real-life study with the SQ® 
grass SLIT-tablet in Germany including 1109 patients 
only 75 (6.8 %) were reported to be concomitantly treated 
with another AIT [11].
The standardised sublingual grass allergy immunother-
apy tablet (SQ® grass SLIT-tablet), GRAZAX® (Phleum 
pratense 75,000 SQ-T/2,800 BAU, ALK-Abelló, Hør-
sholm, Denmark), developed for sublingual application 
in patients with grass pollen induced rhinoconjunctivitis 
and investigated in more than 5600 patients in controlled 
clinical trials in Europe and USA [12–25], is a European 
wide approved SLIT-tablet that was launched in Novem-
ber 2006 in Germany.
AIT has been attributed with altering the natural 
course of the disease, thereby entailing sustained reduc-
tions in symptoms and disease modifying effect [24]. This 
has been demonstrated in placebo-controlled clinical 
trials with the standardised SQ® SCIT product (Alutard 
SQ® Phleum pratense), [26] and also with the SQ® grass 
SLIT-tablet (GRAZAX®), [21, 22].
The safety data obtained for the SQ® grass SLIT-tablet 
during the clinical development program have shown 
that the most frequently reported adverse events (AEs) 
were mild to moderate, transient application-site related 
events with the most common reactions being oral pru-
ritus, mouth oedema, ear pruritus, and throat irritation. 
In clinical practice, the question arises whether the com-
bination of treatment with the SQ® grass SLIT-tablet and 
a concomitant AIT product, applied as sublingual (SLIT) 
or subcutaneous immunotherapy (SCIT), is comparably 
safe and well tolerated as the mono-therapy.
The aim of the present non-interventional, observa-
tional and open-label study was, thus, to investigate the 
safety and tolerability of the SQ® grass SLIT-tablet in 
patients who received a concomitant further AIT dur-




This study was multi-centre, open, uncontrolled, and 
observational according to non-interventional post-
authorization surveillance studies mentioned in the Ger-
man drug law for recording of data concerning tolerability 
and routine application of drugs after marketing authori-
zation. These studies are explicitly excluded from the area 
of application of the EU-guideline on clinical trials [4] 
and are, thus, not conducted according to Good Clini-
cal Practice (GCP) guidelines [27]. All patients included 
were treated with the standardised SQ® grass SLIT-tablet 
(GRAZAX®, ALK-Abelló, Denmark) following the speci-
fications for administration in the Summary of product 
characteristics (SmPC). Data were analysed by epidemio-
logical methods. Centers were distributed all over Ger-
many and were asked to record data on patients in a 
consecutive order dependent on the patient’s willingness 
to participate in the study in order to avoid a selection bias.
Allergy immunotherapy
Treatment with the oral dispersible SQ® grass SLIT-
tablet, GRAZAX® (Phleum pratense 75,000 SQ-T/2,800 
BAU) was initiated after the grass pollen seasons in 2012 
and 2013. The first administration of the SQ® grass SLIT-
tablet was performed at the physician’s office at visit 1 
(V1) where patients stayed for at least 30  min after the 
first dosing, in order to enable patient and physician to 
discuss any side effects. Subsequently, the SQ® grass 
SLIT-tablet was taken by the patient at home. After V1, 
patients were followed at visit 2 (V2) after 1 or 3 months 
treatment dependent on whether 30 or 100 tablets had 
been prescribed at V1. Together with the data on admin-
istration of the SQ® grass SLIT-tablet data on safety 
and tolerability of any SCIT or SLIT products available 
in Germany for routine treatment were planned to be 
recorded if these had been initiated before, at the same 
time or after first administration of the SQ® grass SLIT-
tablet during the observation period of the study.
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Ethics and data protection
According to German drug law, non-interventional 
post-marketing studies are notified to the authorities. 
The study was approved by the Ethics Committee of the 
Landesärztekammer Baden-Württemberg (Reference No. 
F-2011-075) and the consent of the patients for collec-
tion of their data was obtained. The decision of the phy-
sician to prescribe SLIT with the SQ® grass SLIT-tablet 
and concomitant AIT has been taken independently from 
the inclusion of the patient in the study. For recording 
and evaluation of data patients were assigned a 3-digit 
patient number. Direct identification of the patients was 
restricted to the physicians’ offices that participated in 
the study.
Patients
In the study 181 patients were included from 48 aller-
gists’ offices distributed over Germany.
Patients with a diagnosis of grass pollen-induced rhi-
nitis and/or conjunctivitis (according to symptoms and 
skin prick test and/or sIgE) with or without asthma with 
clinically relevant symptoms that were treated with the 
SQ grass SLIT-tablet and a concomitant AIT (SCIT or 
SLIT) and who had no contraindications to a prescrip-
tion according to the SmPC of GRAZAX® were eligible 
to be documented in this study.
Indications according to the SmPC are: Disease-modi-
fying treatment of grass pollen induced rhinitis and con-
junctivitis in adults and children (5 years or older) with 
clinically relevant symptoms and diagnosed with a posi-
tive skin prick test and/or specific IgE test to grass pol-
len. Contraindications are: Hypersensitivity to any of the 
excipients, malignancy or systemic diseases affecting the 
immune system e.g. autoimmune diseases, immune com-
plex diseases or immune deficiency diseases, inflamma-
tory conditions in the oral cavity with severe symptoms 
such as oral lichen planus with ulcerations or severe oral 
mycosis. Patients with uncontrolled or severe asthma 
(in adults: FEV1 < 70 % of predicted value after adequate 
pharmacologic treatment, in children: FEV1  <  80  % of 
predicted value after adequate pharmacologic treatment) 
should not be treated with GRAZAX® immunotherapy.
Assessments
In the present study, safety and tolerability of the SQ® 
grass SLIT-tablet was planned to be assessed when 
administered with concomitant AIT.
Evaluation of tolerability was based on AEs recorded 
by the physician after the first administration of the SQ® 
grass SLIT-tablet, when giving injections of concomitant 
SCIT(s) and recorded by the patient in a diary during 
the observation period. The time schedule and the major 
assessments of the study are illustrated in Fig. 1.
At V1 when the patient was included in the study, 
demographic data and data on the allergy history includ-
ing age at first appearance of symptoms, clinical mani-
festation of the allergy (rhinitis/conjunctivitis/asthma/
atopic dermatitis/other), other allergies, the diagnostics 
performed for the main allergies that were treated by AIT 
(grass pollen and 1 or 2 concomitant allergies), any pre-
vious AIT, and concomitant treatments by AIT or other 
medications due to concomitant diseases were recorded. 
The actual anti-allergic medication used was recorded 
(topical or oral antihistamines/nasal or oral corticoster-
oids/inhaled corticosteroids/inhaled short-acting ß2 ago-
nists (SABA)/inhaled long-acting ß2 agonists (LABA)/
other, to be specified). The first administration of the 
SQ® grass SLIT-tablet was performed in the physician’s 
office where an eventual anti-allergic pre-medication was 
recorded and any AEs that occurred while the patient was 
under supervision for 30 min. An AE was defined as any 
untoward medical occurrence in a patient and which did 
V2      1 or 3






• Demography and Allergy history
• Concomitant AIT
• Diagnostics for main allergies
• Current symptomatic medication
• Adverse events (first administration)
V2 - assessments:
• Adverse events (follow-up period),    
evaluation of patient diary
• Global assessment of tolerability
(patient and physician)
• Study completion / withdrawal
Concomitant AIT 
(SCIT or SLIT)
Concomitant AIT already 
ongoing at V1, or started 




Fig. 1 Study diagram
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not necessarily have a causal relationship with treatment. 
AEs that were possibly related to treatment were classi-
fied as adverse drug reactions (ADRs). The application 
of the SQ® grass SLIT-tablet during home treatment and 
applications of concomitant AIT(s) and side effects were 
recorded by the patient in a diary. Patients were asked to 
specify in the diary the day and clock time of applications 
of the SQ® grass SLIT-tablet and whether the concomi-
tant AIT product was applied on that day; if yes, patients 
were asked to record the clock time of application. Fur-
thermore, patients were instructed to record the symp-
toms of any side effect and to assess the severity of the 
side effect (mild/moderate/severe) together with the time 
of occurrence. Furthermore, the patients were asked to 
record their actions they had taken due to the side effects 
(no action/taking a medication (which product and due 
to which symptoms?)/visit the doctor/discontinuation of 
treatment/something else (what?)). In addition, an over-
all assessment of tolerability (very good/good/moderate/
poor) was performed by patient and physician at V2 as 
final visit of the study.
AEs were specified by the physician in the case report 
form (CRF) as diagnosis or description and assessed by 
intensity (mild/moderate/severe), causality (possible/
unlikely), change of treatment (no change/interrup-
tion/discontinuation), treatment by medication (yes/
no), outcome (recovered/recovered with sequelae/not 
recovered/fatal/unknown) and seriousness (yes/no). An 
AE was assessed as severe when the event considerably 
interfered with the patient’s daily activities. A serious AE 
(SAE) was defined as any medical occurrence or effect 
that was life-threatening, required hospitalization or 
prolongation of hospitalization, resulted in persistent or 
significant disability or incapacity, resulted in death, con-
genital abnormalities or birth defect, or any other event 
judged medically important. The patients came back to 
the physician’s office at V2 after 1–3  months for a new 
prescription, dependent on whether 30 or 100 SQ® grass 
SLIT-tablets had been prescribed after first administra-
tion. At V2 the physician interviewed the patients about 
side effects that had occurred between V1 and V2 during 
home treatment, reviewed the diary and recorded all AEs 
in the CRF including his/her medical assessment accord-
ing to the above-mentioned criteria for specification of 
AEs. Finally, the continuation or discontinuation of treat-
ment and its reasons were recorded.
SAEs were further documented on a separate report 
form, and if applicable according to legal pharmacovigi-
lance procedures, they were notified to the authorities.
Statistics
Data analysis was performed solely by descriptive sta-
tistics using minimum, maximum, median, mean, range 
and standard deviation for continuous data as well as 
frequency distributions for ordinal data. No imputation 
was performed in case of missing data, but all available 
data were used to their full extent. The principal statis-
tical software used was SAS®, version 9.3. No formal 
sample size calculation has been made for this study. 
The primary objective was to record data on safety and 
tolerability of the SQ® grass SLIT-tablet when applied 
with concomitant AIT. To obtain a real-life picture it was 
aimed to engage a large number of physicians in the study 
who recorded data on patients that were routinely treated 
with the SQ® grass SLIT-tablet and one or two concomi-
tant AITs. AEs were coded according to the current ver-
sion of the Medical Dictionary for Regulatory Activities 
(MedDRA). ADRs were displayed for patients and on the 
level of events including multiple occurrences by patient.
Results
Patients
The study was initiated in January 2012 and the last 
patient completed the study in January 2014. Patient 
characteristics and treatment with AIT are displayed in 
Table 1.
First administration of the SQ® grass SLIT-tablet in 
the physician’s office was recorded in 181 patients by 48 
allergist’s offices. The study was planned to record only 
patients who were concomitantly treated with another 
AIT, in 21 patients, however, no concomitant AIT had 
been applied. Therefore, the data are presented separately 
for patients with concomitant AIT (N  =  160), patients 
without concomitant AIT (N  =  21) and total patients 
(N = 181). The majority of patients included in the study 
received predominantly one concomitant SCIT product 
(75.0 %) and in rare cases two (6.3 %) concomitant SCIT 
products, 18.8  % of patients were treated with a single 
concomitant SLIT product. Most patients were con-
comitantly treated against allergy to tree pollen (56.9  % 
SCIT, 60.0  % SLIT), and fewer patients against house 
dust mites (30.8 % SCIT, 26.7 % SLIT); few patients were 
concomitantly treated against allergy to moulds, weed 
pollen, animal dander and wasp venom (4.6  % SCIT, 
13.3  % SLIT). The concomitant AIT had been started 
before the first administration of the SQ® grass SLIT-
tablet in 51.5 % of patients treated with SCIT and 50.0 % 
of patients treated with SLIT; it was initiated at the same 
day of first administration of the SQ® grass SLIT-tablet in 
23.1 % of patients with SCIT and in 39.3 % with SLIT, and 
after first administration of the SQ® grass SLIT-tablet in 
25.4 % with SCIT and 10.7 % with SLIT. In the group of 
patients with an initiation of the concomitant AIT after 
first administration of the SQ® grass SLIT-tablet the 
median period of parallel administration of the SQ® grass 
SLIT-tablet together with concomitant SCIT was 67.2 % 
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(6.6–99.0  %) and with concomitant SLIT 60.9  % (21.3–
87.9 %) of the observation period.
Discontinuations of treatment are shown in Table 2.
Tolerability
A summary of all AEs and ADRs reported during the 
observation period are shown in Table  3. In 29/160 
(18.1 %) patients treated with the SQ® grass SLIT-tablet 
and concomitant AIT, severity of ADRs was assessed 
mild or moderate and assessed severe in 20/160 (12.5 %) 
patients. Treatment with the SQ® grass SLIT-tablet was 
discontinued due to ADRs in 12/160 (7.5  %) patients 
treated with the SQ® grass SLIT-tablet and concomi-
tant AIT. AEs with possible relationship to the SQ® grass 
SLIT-tablet (ADRs) reported in ≥1  % of patients are 
displayed as MedDRA system organ classes (SOCs) and 
preferred terms (PTs) in Table 4. Most frequent reactions 
(in ≥ 5 % of patients) were oral pruritus, throat irritation, 
Table 1 Patient characteristics and treatment with AIT
a Moulds: n = 5; weed pollen: n = 1
b Cat: n = 1; weed pollen: n = 1; wasp venom: n = 1
c Cat: n = 1; moulds: n = 2; weed pollen: n = 1
Concomitant AIT No concomitant AIT All patients treated
Patients, n 160 21 181
Age, years, mean ± SD 32.5 ± 13.9 28.2 ± 13.3 32.0 ± 13.9
Patients 5–11 years, n (%) 10 (6.3) 3 (14.3) 13 (7.2)
Patients 12–17 years, n (%) 13 (8.1) 1 (4.8) 14 (7.7)
Patients ≥18 years, n (%) 137 (85.6) 17 (81.0) 154 (85.1)
Gender, n (%)
 Male 68 (42.5) 11 (52.4) 79 (43.6)
 Female 92 (57.5) 10 (47.6) 102 (56.4)
Age at first diagnosis of allergy, years ± SD 26.8 ± 14.7 23.5 ± 13.5 26.5 ± 14.5
Major manifestations, n (%)
 Rhinitis 156 (97.5) 20 (95.2) 176 (97.2)
 Conjunctivitis 99 (61.9) 16 (76.2) 115 (63.5)
 Asthma 68 (42.5) 4 (19.0) 72 (39.8)
 Atopic dermatitis 14 (8.8) 3 (14.3) 17 (9.4)
Main allergies (multiple ratings), n (%)
 Grass pollen 160 (100.0) 21 (100.0) 181 (100.0)
 Tree pollen 101 (63.1) 7 (33.3) 108 (59.7)
 House dust mite 57 (35.6) 2 (9.5) 59 (32.6)
 Animal hair/dander 3 (1.9) – 3 (1.7)
 Weed pollen 3 (1.9) – 3 (1.7)
 Moulds 7 (4.4) – 7 (3.9)
 Wasp venom 1 (0.6) – 1 (0.6)
History of AIT, n (%) 18 (11.3) 7 (33.3) 25 (13.8)
Treatment with AIT, n (%)
 SQ® grass SLIT-tablet 160 (100.0) 21 (100.0) 181 (100.0)
 Concomitant SCIT 130 (81.3) – 130 (71.8)
 Tree pollen 74 (46.3) – 74 (40.9)
 House dust mite 40 (25.0) – 40 (22.1)
 Other allergen 6 (3.8)a – 6 (3.3)a
 Trees + mites 6 (3.8) – 6 (3.3)
 Trees + other allergen 3 (1.9)b – 3 (1.7)b
 Mites + dog 1 (0.6) – 1 (0.6)
Concomitant SLIT 30 (18.8) – 30 (16.6)
 Tree pollen 18 (11.3) – 18 (9.9)
 House dust mite 8 (5.0) – 8 (4.4)
 Other allergen 4 (2.5)c – 4 (2.2)c
Page 6 of 10Reiber et al. Clin Transl Allergy  (2016) 6:9 
oedema mouth and paraesthesia oral followed by ear 
pruritus, sneezing, pruritus and dysphagia (between 3.3 
and 3.9 % of patients). No serious ADRs according to the 
criteria for seriousness described in the Methods section 
were observed. ADRs related to the concomitant AIT 
occurred in 17 (SCIT, 13.1 %) and 1 (SLIT, 3.3 %) patients 
(Table 5).
Compliance
Patient diaries could be evaluated in 126 patients of the 
total 181 patients (69.6 %) and in 114 patients who had 
received a concomitant AIT (71.3  %). According to the 
diary records, 89 (70.6 %) patients of all patients with a 
diary were compliant by ≥80 % with the daily intake of 
the SQ® grass SLIT-tablet, 25 (19.8 %) by 50–79 % and 12 
(9.5 %) by <50 %.
Discussion
The SQ® grass SLIT-tablet has been launched 2006 in 
Germany according to a European wide approval for 
marketing based on randomised controlled trials dem-
onstrating efficacy, safety and tolerability. In the present 
study, safety and tolerability of the SQ® grass SLIT-tablet 
administered with concomitant AIT (81 % SCIT and 19 % 
SLIT) were assessed in 160 patients in a routine clini-
cal setting. AEs considered related with the SQ® grass 
SLIT-tablet were reported in 49 (30.6 %) patients and in 
18 (11.3  %) patients with the concomitant AIT, discon-
tinuations due to AIT related AEs (ADRs) were recorded 
in 12 (7.5 %) patients; severity of ADRs was assessed in 
29 (18.1  %) mild to moderate and severe in 20 (12.5  %) 
patients. Overall tolerability was assessed “good” or “very 
good” by 91.0 % of patients and 91.6 % of physicians.
Safety data from two studies on a multiple treatment 
in poly-sensitized patients have been discussed in review 
articles by Passalaqua [3] and Calderon [6] published 
recently. In a post marketing survey, treatment with SLIT 
was performed with single allergens or a mixture of aller-
gens in 433 children, out of which 254 received the mix-
ture of several allergens. No increased rates of side effects 
have been observed in the children that received multiple 
allergens [28].
In a retrospective analysis on 147 poly-sensitized 
patients treated with SCIT by one single or two paral-
lel injections of single allergen extracts (various pol-
len, house dust mite, moulds, animal dander and 







Patients 160 21 181
Discontinuation due to
 AEs 14 (8.8) 1 (4.8) 15 (8.3)
 Patient moved 1 (0.6) 1 (4.8) 2 (1.1)
 Withdrawal of consent 1 (0.6) – 1 (0.6)
 Tablet application too complicated 1 (0.6) – 1 (0.6)
 Not returned after 1st administration of SQ® grass SLIT-tablet 2 (1.3) 1 (4.8) 3 (1.7)
Patients continuing treatment 141 (88.1) 18 (85.7) 159 (87.8)




AIT n (%), E
All patients treated
n (%), E
Patients 160 21 181
AEs, total 58 (36.3), 402 8 (38.1), 37 66 (36.5), 439
ADRs: SQ® grass SLIT-tablet 49 (30.6), 358 8 (38.1), 37 57 (31.5), 395
 Medical measures (no) 39 (24.4), 294 5 (23.8), 33 44 (24.3), 327
 Medical measures (yes) 10 (6.3), 64 3 (14.3), 4 13 (7.2), 68
 Severity: mild 15 (9.4), 136 5 (23.8), 34 20 (11.0), 170
  Moderate 14 (8.8), 140 3 (14.3), 3 17 (9.4), 143
  Severe 20 (12.5), 80 – 20 (11.0), 80
  Missing value –, 2 – –, 2
 SQ® grass SLIT-tablet discontinued 12 (7.5), 25 1 (4.8), 2 13 (7.2), 27
ADRs: concomitant AIT 18 (11.3), 99 – 18 (9.9), 99
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Table 4 ADRs related to the SQ® grass SLIT-tablet in ≥1 % of patients








Patients 160 21 181
All patients with ADRs 49 (30.6), 358 8 (38.1), 37 57 (31.5), 395
Ear and labyrinth disorders 8 (5.0), 18 – 8 (4.4), 18
 Ear pruritus 7 (4.4), 17 – 7 (3.9), 17
Eye disorders 6 (3.8), 11 – 6 (3.3), 11
 Eye pruritus 3 (1.9), 4 – 3 (1.7), 4
 Eye irritation 2 (1.3), 6 – 2 (1.1), 6
Gastrointestinal disorders 35 (21.9), 131 5 (23.8), 29 40 (22.1), 160
 Oral pruritus 14 (8.8), 34 1 (4.8), 6 15 (8.3), 40
 Oedema mouth 10 (6.3), 16 3 (14.3), 3 13 (7.2), 19
 Paraesthesia oral 8 (5.0), 21 3 (14.3), 10 11 (6.1), 31
 Dysphagia 6 (3.8), 11 – 6 (3.3), 11
 Hypoaesthesia oral 4 (2.5), 5 1 (4.8), 2 5 (2.8), 7
 Oral discomfort 4 (2.5), 6 – 4 (2.2), 6
 Lip swelling 2 (1.3), 2 2 (9.5), 6 4 (2.2), 8
 Tongue pruritus 3 (1.9), 4 – 3 (1.7), 4
 Nausea 3 (1.9), 4 – 3 (1.7), 4
 Swollen tongue 2 (1.3), 2 – 2 (1.1), 2
 Lip pruritus 2 (1.3), 2 – 2 (1.1), 2
 Glossodynia 2 (1.3), 4 – 2 (1.1), 4
 Abdominal pain upper 2 (1.3), 2 – 2 (1.1), 2
General disorders and administration site conditions 11 (6.9), 38 – 11 (6.1), 38
 Fatigue 3 (1.9), 13 – 3 (1.7), 13
 Sensation of foreign body 3 (1.9), 8 – 3 (1.7), 8
 Injection site pruritus 2 (1.3), 2 – 2 (1.1), 2
Infections and infestations 2 (1.3), 6 – 2 (1.1), 6
 Nasopharyngitis 2 (1.3), 6 – 2 (1.1), 6
Nervous system disorders 6 (3.8), 26 2 (9.5), 3 8 (4.4), 29
 Headache 3 (1.9), 19 2 (9.5), 3 5 (2.8), 22
 Dizziness 2 (1.3), 3 – 2 (1.1), 3
Respiratory, thoracic and mediastinal disorders 30 (18.8), 94 3 (14.3), 4 33 (18.2), 98
 Throat irritation 13 (8.1), 34 – 13 (7.2), 34
 Sneezing 7 (4.4), 11 – 7 (3.9), 11
 Cough 5 (3.1), 8 – 5 (2.8), 8
 Oropharyngeal pain 3 (1.9), 8 – 3 (1.7), 8
 Pharyngeal oedema 2 (1.3), 3 1 (4.8), 2 3 (1.7), 5
 Nasal discomfort 2 (1.3), 2 1 (4.8), 1 3 (1.7), 3
 Rhinorrhea 3 (1.9), 4 – 3 (1.7), 4
 Dyspnoea 2 (1.3), 5 – 2 (1.1), 5
 Nasal congestion 2 (1.3), 5 – 2 (1.1), 5
 Rhinitis allergic 2 (1.3), 2 – 2 (1.1), 2
 Dry throat 2 (1.3), 2 – 2 (1.1), 2
Skin and subcutaneous disorders 9 (5.6), 23 1 (4.8), 1 10 (5.5), 24
 Pruritus 6 (3.8), 17 – 6 (3.3), 17
 Rash 3 (1.9), 3 – 3 (1.7), 3
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Hymenoptera venom) a slightly higher but not signifi-
cant rate of ADRs was observed during the dose-increase 
phase in the parallel injection group [6, 29]. To our 
knowledge, no further systematically recorded data on 
the safety and tolerability of SLIT (i.e. SLIT-tablet) con-
comitantly administered with other AIT (SCIT or SLIT) 
have been published.
In a previous non-interventional study with the SQ® 
grass SLIT-tablet performed in Germany only a minor 
number of poly-sensitized patients with multiple clini-
cal relevant allergies was treated with more than one 
AIT product [11]. The number of patients treated with 
the SQ® grass SLIT-tablet and concomitant AIT avail-
able for collecting data on safety and tolerability within 
a real-life setting appears, thus, to be limited. Our 
non-interventional, observational study was designed 
to observe the first 1–3  months of treatment with the 
SQ® grass SLIT-tablet because the highest frequency of 
adverse reactions is known to occur at first administra-
tion and to decline with longer duration of treatment 
due to the increasing induction of tolerance to grass 
allergens by an effective treatment [12–25, 30]. The 
majority of patients who started treatment with the SQ® 
grass SLIT-tablet included in our study were treated 
concomitantly with one further pollen allergen prod-
uct, i.e. tree pollen allergens (60 %), and fewer patients 
with one perennial allergen product, i.e. house dust 
mite allergens (30 %). Reflecting the general use of AIT 
in Germany, most patients were treated with one con-
comitant AIT product, predominantly SCIT (75 %) and 
fewer patients (18.8  %) with a single concomitant SLIT 
product and only a small number with two concomi-
tant AIT products, all SCIT (6.3 %). A small subgroup of 
patients (11.6 %) in our study did not receive a concomi-
tant AIT. Data on this group is presented separately, 
but the number of patients is too small to be used for 
comparison of the incidence of ADRs for patients with 
and without concomitant AIT. Therefore, we used data 
from previous non-interventional studies with the SQ® 
grass SLIT-tablet in the real-life setting for comparison 
of the incidence of ADRs in the group of patients with 
concomitant AIT of our study [11, 31, 32]. The observed 
incidence of ADRs of 31.5  % of 181 total patients in 
our study and of 30.6  % in 160 patients with concomi-
tant AIT was at a similar level as in two previous stud-
ies with the SQ® grass SLIT-tablet with a higher number 
of patients, one with 1109 adult patients and 27.0  % of 
patients with ADRs [11] and one with 1761 patients (964 
adults and 797 children and adolescents) and 31.8 % of 
patients with ADRs [31], but lower than in another study 
with intra-seasonal initiation of the SQ® grass SLIT-tab-
let in 662 adult patients in which ADRs were observed in 
49.8 % of patients [32]. ADRs in our study were of mild 
to moderate severity in the majority of patients (20.4 %) 
and in fewer patients severe (11.0 %). The rate of discon-
tinuations due to ADRs (7.5 %) in patients who received 
a concomitant AIT was similar as in the previous non-
interventional studies [11, 31, 32].
The tolerability profile observed in our study was com-
parable to the one observed in the previous non-inter-
ventional real-life studies and controlled clinical trials 
with the SQ® grass SLIT-tablet [11–25, 31, 32]. Most 
Table 5 ADRs related to the concomitant AIT in ≥1 % of patients (in at least one treatment group)








Patients 130 30 160
All patients with ADRs 17 (13.1), 96 1 (3.3), 3 18 (11.3), 99
Ear and labyrinth disorders 3 (2.3), 5 – 3 (1.9), 5
 Ear pruritus 2 (1.5), 3 – 2 (1.3), 3
Gastrointestinal disorders 4 (3.1), 10 1 (3.3), 1 5 (3.1), 11
 Abdominal pain – 1 (3.3), 1 1 (0.6), 1
General disorders and administration site conditions 13 (10.0), 39 – 13 (8.1), 39
 Fatigue 3 (2.3), 12 – 3 (1.9), 12
 Injection site pruritus 4 (3.1), 7 – 4 (2.5), 7
 Injection site swelling 5 (3.8), 5 – 5 (3.1), 5
Respiratory, thoracic and mediastinal disorders 6 (4.6), 20 1 (3.3), 1 7 (4.4), 21
 Oropharyngeal pain – 1 (3.3), 1 1 (0.6), 1
 Sneezing 3 (2.3), 4 – 3 (1.9), 4
Skin and subcutaneous tissue disorders 4 (3.1), 9 1 (3.3), 1 5 (3.1), 10
 Pruritus 2 (1.5), 7 – 2 (1.3), 7
 Rash 1 (0.8), 1 1 (3.3), 1 2 (1.3), 2
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frequent reactions observed in our study were local reac-
tions at the application site of the SQ® grass SLIT-tablet 
in the mouth as oral pruritus, throat irritation, oedema 
mouth and paraesthesia oral (≥5 % of patients). Clearly 
typical side effects of SCIT were observed in the group of 
patients with concomitant AIT, but no interaction with 
side effects typical for the SQ® grass SLIT-tablet was 
detected. The rate of reactions considered by the phy-
sicians related to the concomitant AIT was low, overall 
(11.3 % of the 160 patients with a concomitant AIT).
Limitations of our study are those of a prospective, 
open-label, un-controlled observational study in routine 
treatment. In order to minimize a potential investiga-
tor bias sites distributed all over Germany were involved. 
For reduction of a potential selection bias physicians were 
asked to include patients in a consecutive order according 
to the consent of the patients to be included in the study. 
The number of 160 patients with concomitant AIT and 
safety and tolerability data allows detecting ADRs of inci-
dence 2 % with a probability of 95 % at least once. The inter-
pretation of the safety and tolerability data from our study 
is, therefore, limited to a comparison of data for frequencies 
of ADRs with data from previous studies of similar design 
(including less than 10 % of patients with concomitant AIT) 
and to a comparison of the safety and tolerability profile for 
ADRs known to be most frequent for the application of the 
SQ® grass SLIT-tablet during the first 1–3 months of treat-
ment. This study period is short with respect to the evalua-
tion of AEs by a concomitant SCIT treatment.
Conclusions
In conclusion no increase in frequency of AEs compared 
with data from previous studies or change in the toler-
ability profile was observed when the SQ® grass SLIT-
tablet was administered with concomitant SCIT or SLIT 
in real life.
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